No regulatory agency currently recognizes aging as an indication, and no biological age biomarker is accepted as a validated endpoint. What has shifted is that a regulator, a payer and a federal funder have each publicly identified the same bottleneck — validated surrogate endpoints — while three concrete proposals, including Intrinsic Capacity composites and a $34.5 million ARPA-H-funded effort to build an FDA-grade functional score, are now on the table.
Key Points
- FDA, CMS and ARPA-H independently named surrogate endpoints as the bottleneck
- GLP-1s meet three of four gerotherapeutic criteria; healthspan trial missing
- THRIVE coalition funded to build sub-$100 at-home Intrinsic Capacity score
Longevity Analysis
Measurement, not molecules, is the rate-limiting step. An endpoint built on Intrinsic Capacity — mobility, cognition, vitality, sensory and psychological function — would anchor approval to how well the body actually moves, thinks and recovers rather than to a single disease label, and a sub-$100 at-home version would put that same readout in individual hands years before any drug clears review. The GLP-1 caveat is instructive: a weight-lowering intervention that protects a population averaging a BMI near 29.5 becomes a liability near 22, where preserving lean mass is the priority — a reminder that benefit depends on correctly reading the individual's starting state.
Original published by Longevity.Technology, by Eleanor Garth.